- Molecular NameAzlocillin
- SynonymAzlocilina [INN-Spanish]; Azlocillin sodium salt; Azlocilline [INN-French]; Azlocillinum [INN-Latin]
- Weight461.499
- Drugbank_IDDB01061
- ACS_NO37091-66-0
- Show 2D model
- LogP (experiment)-0.046
- LogP (predicted, AB/LogP v2.0)1.2
- pkaN/A
- LogD (pH=7, predicted)-2.76
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.18
- LogSw (predicted, AB/LogsW2.0)6.22
- Sw (mg/ml) (predicted, ACD/Labs)0.64
- No.of HBond Donors4
- No.of HBond Acceptors11
- No.of Rotatable Bonds5
- TPSA173.45
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn acylampicillin antibiotic with an extended spectrum of activity and greater in vitro potency than the carboxy penicillins.
- Absorption_value0.0
- Absorption (description)Azlocillin is poorly absorbed from the gastro-intestinal tract but is widely distributed following intravenous administration in body tissues and fluids.
- Caco_2N/A
- Bioavailability0.0
- Protein binding33.0
- Volume of distribution (VD)0.22 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is metabolised to a limited extent
- Half life1 h
- ExcretionAbout 50 to 70% of a dose is excreted unchanged in the urine by glomerular filtration and tubular secretion. This occurs within 24 h of administration, therefore, producing high urinary concentrations. It is partly excreted in bile. Concomitant administration of probenecid increases plasma concentrations. It can be removed by haemodialysis.
- Urinary ExcretionN/A
- CleranceSerum clearance, 153 mL/min/1.73 m2.
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A